clinical trial · NCT04343248
Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Post-Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses in Elderly Residents of Long-Term Care Facilities (LTCF)
Romark Laboratories L.C.·phase3·terminated·n = 190
COVID-19Viral Respiratory IllnessesNitazoxanidePlaceboVitamin Super B-Complex
brief summary
Trial to evaluate the efficacy and safety of NTZ for post-exposure prophylaxis of COVID-19 and other VRIs in elderly LTCF residents.
started
May 12, 2020
primary completion
Feb 1, 2021
completion
Feb 1, 2021
last updated
Jul 8, 2024
detailed description
Multicenter, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of NTZ for post-exposure prophylaxis of COVID-19 and other VRIs in elderly LTCF residents.
official title
A Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Post-Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses in Elderly Residents of Long-Term Care Facilities (LTCF)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol